Henry Schein (NASDAQ:HSIC) Releases FY 2024 Earnings Guidance

Henry Schein (NASDAQ:HSIC) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 4.740-4.740 for the period, compared to the consensus estimate of 4.770. The company issued revenue guidance of $12.7 billion-$12.7 billion, compared to the consensus revenue estimate of $12.8 billion. Henry Schein also updated its Q4 2024 guidance to 1.190-1.190 EPS.

Henry Schein Stock Performance

Shares of HSIC stock opened at $79.77 on Thursday. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46. The stock has a 50 day simple moving average of $73.19 and a 200-day simple moving average of $71.27. The company has a market cap of $9.95 billion, a price-to-earnings ratio of 32.81, a price-to-earnings-growth ratio of 2.04 and a beta of 0.89. Henry Schein has a 12-month low of $63.67 and a 12-month high of $82.63.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, November 5th. The company reported $1.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.05. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The company had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.24 billion. During the same period last year, the company posted $1.32 earnings per share. The firm’s quarterly revenue was up .4% compared to the same quarter last year. On average, equities analysts forecast that Henry Schein will post 4.78 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on HSIC shares. StockNews.com upgraded shares of Henry Schein from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. Mizuho assumed coverage on Henry Schein in a report on Wednesday, December 4th. They issued a “neutral” rating and a $75.00 price target for the company. Jefferies Financial Group boosted their target price on Henry Schein from $77.00 to $80.00 and gave the stock a “hold” rating in a report on Thursday, January 23rd. Bank of America upgraded shares of Henry Schein from an “underperform” rating to a “buy” rating and boosted their price objective for the stock from $69.00 to $84.00 in a research note on Monday, January 6th. Finally, Evercore ISI raised their target price on shares of Henry Schein from $70.00 to $74.00 and gave the company an “in-line” rating in a research note on Tuesday, October 8th. Seven research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $80.10.

Insider Transactions at Henry Schein

In related news, COO Michael S. Ettinger sold 12,240 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $75.00, for a total transaction of $918,000.00. Following the transaction, the chief operating officer now owns 87,706 shares of the company’s stock, valued at approximately $6,577,950. This trade represents a 12.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.14% of the stock is currently owned by insiders.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.